Enantiomeric characterization and structure elucidation of Otamixaban
Otamixaban is a potent (Ki=0.5Â nM) fXa inhibitor currently in late-stage clinical development at Sanofi for the management of acute coronary syndrome. Being unproductive in obtaining a suitable crystal of Otamixaban, the required enantiomeric characterization has been accomplished using vibrational...
Main Authors: | , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2014-06-01
|
Series: | Journal of Pharmaceutical Analysis |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2095177913001081 |